Name | BC-N102 |
---|
Description | BC-N102 is a first-in-class novel small molecule inhibitor for targeting oncogenic and hormonal signaling in ER-positive breast cancer.BC-N102 exhibits anticancer activity against breast cancer cell lines via interfering with cell cycle regulatory proteins and hormonal receptors signaling in vitro (IC50=0.04-10 uM), no significant activities against a normal breast cell line.BC-N102 exhibits potent antitumor activity at tolerated doses in an ER+ human xenograft breast cancer model.BC-N102 induces arrest of the cell cycle at G0/G1 phase, downregulates the expression of CDK2 and CDK4 independent of the ER in breast cancer cell lines. |
---|---|
References | 1. Bashir Lawal, et al. Int J Biol Sci. 2021 Jul 25;17(12):3224-3238. |
Molecular Formula | C18H13ClN2Os |
---|---|
Molecular Weight | 340.825 |